MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.63 CNY | +5.44% |
|
+5.62% | +26.67% |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 12,889 | - | - |
| Enterprise Value (EV) 1 | 12,889 | 12,889 | 12,889 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | 3.58 x | 3.17 x | 2.83 x |
| EV / Revenue | 3.58 x | 3.17 x | 2.83 x |
| EV / EBITDA | 20.6 x | 17.8 x | 14.9 x |
| EV / FCF | 36.8 x | 36.4 x | 20.5 x |
| FCF Yield | 2.72% | 2.75% | 4.88% |
| Price to Book | 3.2 x | 2.9 x | 2.59 x |
| Nbr of stocks (in thousands) | 4,31,054 | - | - |
| Reference price 2 | 30.63 | 30.63 | 30.63 |
| Announcement Date | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales 1 | 3,600 | 4,067 | 4,559 |
| EBITDA 1 | 626 | 723 | 865 |
| EBIT 1 | 657 | 747 | 899 |
| Operating Margin | 18.25% | 18.37% | 19.72% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | - | - | - |
| Free Cash Flow 1 | 350.5 | 353.8 | 628.8 |
| FCF margin | 9.74% | 8.7% | 13.79% |
| FCF Conversion (EBITDA) | 55.99% | 48.94% | 72.7% |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt | - | - | - |
| Net Cash position | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow 1 | 350 | 354 | 629 |
| ROE (net income / shareholders' equity) | 13.4% | 13.8% | 14.8% |
| ROA (Net income/ Total Assets) | 10.7% | 11.1% | 12% |
| Assets | - | - | - |
| Book Value Per Share 2 | 9.560 | 10.60 | 11.80 |
| Cash Flow per Share | - | - | - |
| Capex 1 | 71 | 176 | 80.6 |
| Capex / Sales | 1.97% | 4.32% | 1.77% |
| Announcement Date | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +26.67% | 1.83B | |
| +21.28% | 44.4B | |
| +24.60% | 23.03B | |
| +18.48% | 15.14B | |
| +12.87% | 13.12B | |
| +44.67% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.52B |
- Stock Market
- Equities
- 600993 Stock
- Financials Mayinglong Pharmaceutical Group Co., LTD.
